Emerging drugs for the treatment of light chain amyloidosis
Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insol...
Read moreSystemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insol...
Read moreOn Tuesday, July 14, the U.S. Food & Drug Administration’s ODAC (the Oncologic Drugs Advisory Committee)...
Read moreOn May 28, 2020, Karyopharm presented positive data from their BOSTON study at the American Society of Cl...
Read moreTopline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan fluf...
Read moreWhat was the role of Myeloma Canada in creating these guidelines? Myeloma Canada provided logistic and...
Read moreThe Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved ...
Read moreJoin our community and sign up for our newsletter.